Solanezumab slowed Alzheimer's by 30% in a trial earlier this year. Find out what it's maker, Ely Lilly, plans for the next step.
Read more »
Sunday, December 16, 2012
Solanezumab, a Top Alzheimer's Experimental Drug, Launches New Phase 3 Trial
Labels:
Clinical Trials •
Research
Solanezumab slowed Alzheimer's by 30% in a trial earlier this year. Find out what it's maker, Ely Lilly, plans for the next step.
Read more »
